Digital Regulators open the AI floodgates in life sciences In 2026, biopharma will move from proving AI works to proving it can be trusted at scale.
Sales & Marketing Sponsored Beyond the grid: Rethinking tracking studies for pharma’s ne... As the healthcare landscape continues to evolve rapidly, the tools used to understand it must keep pace.
Digital Sponsored What does it mean to have an AI-first mindset in pharma? The importance of AI in pharma and life sciences cannot be overstated.
R&D Ben Sidders on integrating causality in AI for R&D success Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.
R&D Post-hype, pre-value: The real AI-pharma shift starts now The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.
Digital Why security-first design is the fix to stalling AI pilot to... For AI to be transformative in the pharmaceutical industry, it must be designed with a security-first approach.
News FDA approves higher Wegovy dose via 4th priority voucher The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
